Genflow Biosciences (LON:GENF, OTCQB:GENFF, FRA:WQ5) is moving into a more consequential phase, with Dr Eric Leire outlining how promising dog study data, a potentially differentiated glaucoma approach and fresh non-dilutive funding are sharpening the company’s commercial and clinical trajectory. In this interview, he sets out where value could emerge next, from licensing discussions in animal health to late-stage MASH positioning and upcoming IP milestones.
KEY MOMENTS
00:24 – Promising dog study update.
00:42 – Glaucoma strategy targets retinal degeneration.
01:27 – Sarcopenia progress and platform shift.
01:45 – Funding boost and €4 million grant.
02:45 – Large market opportunities outlined.
05:06 – Near-term catalysts for investors.
06:42 – Glaucoma data and conference plans ahead.
07:03 – IP progress could strengthen valuation.
Genflow Biosciences is a biotechnology company developing therapies targeting age-related diseases, including MASH, glaucoma and sarcopenia.
